Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propiomazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | MTOR | P42345 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Propiomazine SCHEMBL6910697 | 1.00 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL29370554 | 1.00 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL29609596 | 1.00 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL30903904 | 0.99 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL141677 | 0.99 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL6372719 | 0.99 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL720224 | 0.98 | CHRM2 (0.96) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL3863991 | 0.94 | CHRM2 (0.88) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| SCHEMBL10368273 | 0.88 | CHRM2 (0.79) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Aceprometazine SCHEMBL142393 | 0.88 | HTR1A (0.79) | CHRM2HTR1ACHRM1ADRA1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240050442-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | UNIVERSITÉ COTE D'AZUR (FR) | 2024-02-15 | — | — | US | claimed |
| EP-4255437-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | Centre National de la Recherche Scientifique (FR) | 2023-10-11 | — | — | EP | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| WO-2022122688-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-16 | — | — | WO | claimed |
| WO-2002005851-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6140324-A | ADMINISTERING TACHYKININ ANTAGONIST AND MUSCARINIC ANTAGONIST AND/OR ANTIHISTAMINE, SUCH THAT THEY GIVE EFFECTIVE RELIEF FROM MOTION SICKNESS | MERCK SHARP & DOHME LTD. (GB) | 2000-10-31 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1997002824-A1 | USE OF A TACHYKININ ANTAGONIST AND A MUSCARINIC ANTAGONIST AND/OR AN ANTIHISTAMINE TO TREAT MOTION SICKNESS | MERCK SHARP & DOHME LIMITED (GB) | 1997-01-30 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-4749700-A | NASAL ADMINISTRATION LOWER DOSAGE | NASTECH PHARMACEUTICAL CO, INC. (US) | 1988-06-07 | — | — | US | claimed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | claimed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050442-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | GRIK5, HTR5A, CYP3A5 | HRH1 2361/4885CHRM2 2329/4885HTR1A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.